Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
← catalyst calendarNCT06131983 · readout in 865 d
Sponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
16
Countries
Australia, Canada, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-19 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Dystrophy, Facioscapulohumeral
Interventions
- Drug: SRP-1001 for Injection — also filed as ARO-DUX4 for Injection
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events Over Time Through End of Study
measured Part 1: Up to Day 90; Part 2: Up to Day 360
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed